

Aaron P Thrift

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2434829/publications.pdf>

Version: 2024-02-01

158
papers

6,378
citations

101384

36
h-index

82410

72
g-index

161
all docs

161
docs citations

161
times ranked

8197
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden of Gastric Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 534-542.	2.4	775
2	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1828-1837.e2.	0.6	490
3	Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. <i>Gastroenterology</i> , 2017, 152, 812-820.e5.	0.6	339
4	Global epidemiology and burden of HCV infection and HCV-related disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 122-132.	8.2	317
5	The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. <i>Annals of Oncology</i> , 2012, 23, 3155-3162.	0.6	298
6	The epidemic of oesophageal carcinoma: Where are we now?. <i>Cancer Epidemiology</i> , 2016, 41, 88-95.	0.8	217
7	Burden of Pancreatic Cancer: From Epidemiology to Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 876-884.	2.4	166
8	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 61-71.e15.	2.4	159
9	Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 432-443.	8.2	144
10	Obesity and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	132
11	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 66, 355-362.	1.8	104
12	Age at Onset of GERD Symptoms Predicts Risk of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2013, 108, 915-922.	0.2	88
13	Alcohol, smoking and risk of oesophago-gastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 509-517.	1.0	79
14	Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1988-1996.	1.1	75
15	Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. <i>Gut</i> , 2022, 71, 1053-1061.	6.1	74
16	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	0.9	71
17	Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1207-1217.e4.	2.4	71
18	A Model to Determine Absolute Risk for Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 138-144.e2.	2.4	68

#	ARTICLE	IF	CITATIONS
19	A Clinical Risk Prediction Model for Barrett Esophagus. <i>Cancer Prevention Research</i> , 2012, 5, 1115-1123.	0.7	67
20	Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1024-1031.	1.1	67
21	Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. <i>Gastroenterology</i> , 2018, 154, 1273-1281.e3.	0.6	67
22	A Multibiomarker Risk Score Helps Predict Risk for Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1267-1271.	2.4	66
23	Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. <i>PLoS ONE</i> , 2021, 16, e0252164.	1.1	64
24	Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. <i>Gastroenterology</i> , 2018, 155, 316-326.e6.	0.6	60
25	Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. <i>International Journal of Epidemiology</i> , 2018, 47, 966-975.	0.9	59
26	Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1148-1155.	0.2	57
27	Alcohol and the Risk of Barrett's Esophagus: A Pooled Analysis from the International BEACON Consortium. <i>American Journal of Gastroenterology</i> , 2014, 109, 1586-1594.	0.2	55
28	Mendelian randomization study of height and risk of colorectal cancer. <i>International Journal of Epidemiology</i> , 2015, 44, 662-672.	0.9	55
29	The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. <i>International Journal of Cancer</i> , 2012, 131, E759-68.	2.3	52
30	Helicobacter pylori infection and the risks of Barrett's oesophagus: A population-based case-control study. <i>International Journal of Cancer</i> , 2012, 130, 2407-2416.	2.3	51
31	Statin use and risk of liver cancer: Evidence from two population-based studies. <i>International Journal of Cancer</i> , 2020, 146, 1250-1260.	2.3	48
32	Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 20-36.	1.9	48
33	Gastric Cancer Epidemiology. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 425-439.	0.6	48
34	No Significant Effects of Smoking or Alcohol Consumption on Risk of Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2014, 59, 108-116.	1.1	46
35	Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1229-1236.e4.	2.4	41
36	Risk factors and populations at risk: Selection of patients for screening for Barrett's oesophagus. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 41-50.	1.0	40

#	ARTICLE	IF	CITATIONS
37	Clinical Manifestations of Helicobacter pyloriâ€“Negative Gastritis. Clinical Gastroenterology and Hepatology, 2017, 15, 1037-1046.e3.	2.4	40
38	A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. Nature Communications, 2021, 12, 246.	5.8	39
39	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, 2017, 66, 1739-1747.	6.1	38
40	Factors Associated With Recurrence of Barrettâ€™s Esophagus After Radiofrequency Ablation. Clinical Gastroenterology and Hepatology, 2019, 17, 65-72.e5.	2.4	37
41	Proton pump inhibitor and histamineâ€“2 receptor antagonist use and risk of liver cancer in two populationâ€“based studies. Alimentary Pharmacology and Therapeutics, 2018, 48, 55-64.	1.9	36
42	Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology, 2023, 77, 997-1005.	3.6	36
43	Risk Factors for Barrettâ€™s Esophagus Compared Between African Americans and Non-Hispanic Whites. American Journal of Gastroenterology, 2014, 109, 1870-1880.	0.2	34
44	Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. American Journal of Gastroenterology, 2020, 115, 381-387.	0.2	34
45	Prevalence of Barrettâ€™s esophagus and performance of societalâ€“screening guidelines in an unreferral primary care population of U.S. veterans. Gastrointestinal Endoscopy, 2021, 93, 409-419.e1.	0.5	34
46	The effect of obesity on pregnancy outcomes among Australian Indigenous and nonâ€“Indigenous women. Medical Journal of Australia, 2014, 201, 592-595.	0.8	32
47	Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested caseâ€“control study in <sc>US</sc> male veterans. Alimentary Pharmacology and Therapeutics, 2018, 48, 469-477.	1.9	32
48	Melanoma Incidence Among Non-Hispanic Whites in All 50 US States From 2001 Through 2015. Journal of the National Cancer Institute, 2020, 112, 533-539.	3.0	32
49	A Model to Predict the Risk of Keratinocyte Carcinomas. Journal of Investigative Dermatology, 2016, 136, 1247-1254.	0.3	31
50	Risk of Esophageal Adenocarcinoma Decreases With Height, Based on Consortium Analysis and Confirmed by Mendelian Randomization. Clinical Gastroenterology and Hepatology, 2014, 12, 1667-1676.e1.	2.4	30
51	Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clinical Gastroenterology and Hepatology, 2019, 17, 2117-2125.e3.	2.4	29
52	The use of nonsteroidal anti-inflammatory drugs and the risk of Barrettâ€™s oesophagus. Alimentary Pharmacology and Therapeutics, 2011, 34, 1235-1244.	1.9	28
53	Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2016, 111, 1528-1535.	0.2	28
54	The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A retrospective cohort Study of united States Veterans. American Journal of Gastroenterology, 2018, 113, 1310.	0.2	28

#	ARTICLE	IF	CITATIONS
55	Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. <i>Cancer Causes and Control</i> , 2012, 23, 555-564.	0.8	27
56	Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. <i>Digestive Diseases and Sciences</i> , 2017, 62, 526-533.	1.1	27
57	Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 88-94.	1.1	27
58	Are Non-HIV Malignancies Increased in the HIV-Infected Population?. <i>Current Infectious Disease Reports</i> , 2018, 20, 22.	1.3	26
59	Fat Mass by Bioelectrical Impedance Analysis is not Associated With Increased Risk of Barrett Esophagus. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 218-223.	1.1	25
60	Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3112-3119.	1.1	25
61	Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 657-665.e13.	2.4	25
62	Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2021, 31, 1-26.	0.6	25
63	Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. <i>Cancer Causes and Control</i> , 2021, 32, 317-325.	0.8	25
64	Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 330-332.	2.4	24
65	Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1678-1680.	2.4	23
66	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2439-2451.	1.1	23
67	Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 367-372.	1.1	22
68	Trends in the Incidence of Pancreatic Adenocarcinoma in All 50 United States Examined Through an Age-Period-Cohort Analysis. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa033.	1.4	22
69	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, 34.	2.8	22
70	Can we really predict risk of cancer?. <i>Cancer Epidemiology</i> , 2013, 37, 349-352.	0.8	21
71	Metabolic syndrome and the risk of Barrett's oesophagus in white males. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1182-1189.	1.9	21
72	Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018.. <i>Preventive Medicine</i> , 2022, 154, 106903.	1.6	21

#	ARTICLE	IF	CITATIONS
73	Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Digestive Diseases and Sciences, 2020, 65, 2403-2411.	1.1	20
74	Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. Journal of Hepatology, 2022, 76, 294-301.	1.8	20
75	External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clinical Gastroenterology and Hepatology, 2017, 15, 1124-1126.	2.4	19
76	Validation of HIV-infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Medicine, 2019, 20, 567-570.	1.0	19
77	Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Digestive Diseases and Sciences, 2021, 66, 912-916.	1.1	19
78	International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence. American Journal of Gastroenterology, 2021, 116, 1072-1076.	0.2	19
79	Trends in the incidence of early-onset colorectal cancer in all 50 United States from 2001 through 2017. Cancer, 2022, 128, 299-310.	2.0	19
80	Diagnostics for Pleiotropy in Mendelian Randomization Studies: Global and Individual Tests for Direct Effects. American Journal of Epidemiology, 2018, 187, 2672-2680.	1.6	18
81	External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia. Alimentary Pharmacology and Therapeutics, 2019, 49, 1274-1281.	1.9	18
82	Impact of cap-assisted colonoscopy on the learning curve and quality in colonoscopy: a randomized controlled trial. Gastrointestinal Endoscopy, 2018, 87, 723-732.e3.	0.5	17
83	Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population. Clinical Gastroenterology and Hepatology, 2021, 19, 269-276.e3.	2.4	17
84	Symptoms of Obstructive Sleep Apnea, Gastroesophageal Reflux and the Risk of Barrett's Esophagus in a Population-Based Case-Control Study. PLoS ONE, 2015, 10, e0129836.	1.1	16
85	The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. American Journal of Gastroenterology, 2017, 112, 1049-1055.	0.2	16
86	Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1616-1621.e1.	2.4	16
87	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2018, 16, 1598-1606.e4.	2.4	16
88	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clinical Gastroenterology and Hepatology, 2019, 17, 2227-2235.e1.	2.4	16
89	Decreasing Overall and Inappropriate Proton Pump Inhibitor Use: A Perspective From a Large Safety-Net Healthcare System. Clinical Gastroenterology and Hepatology, 2020, 18, 763-766.e2.	2.4	16
90	Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2020, 159, 2065-2076.e1.	0.6	16

#	ARTICLE	IF	CITATIONS
91	Evaluating the Revised American Society for Gastrointestinal Endoscopy Guidelines for Common Bile Duct Stone Diagnosis. <i>Clinical Endoscopy</i> , 2021, 54, 269-274.	0.6	16
92	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	2.9	15
93	Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. <i>Gastroenterology</i> , 2019, 156, 43-45.	0.6	15
94	Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. <i>PLoS ONE</i> , 2019, 14, e0214721.	1.1	14
95	Unravelling the Riddle of Gastroesophageal Reflux Disease, Obesity, and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2273-2275.	2.4	13
96	High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1355-1358.	2.4	13
97	Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. <i>Cancer</i> , 2019, 125, 4210-4223.	2.0	13
98	Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancer. <i>Cancer Epidemiology</i> , 2016, 44, 1-4.	0.8	12
99	Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1412-1419.e3.	2.4	12
100	Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 769-772.	2.4	12
101	Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 310-312.	2.4	12
102	Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2701-2709.e3.	2.4	12
103	Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 319-324.	1.0	11
104	Increasing Incidence of Advanced Non-cardia Gastric Cancers Among Younger Hispanics in the USA. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1669-1672.	1.1	11
105	Effects of Physical Activity on Melatonin Levels in Previously Sedentary Men and Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1696-1699.	1.1	10
106	Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1965-1967.	2.4	10
107	Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa322.	0.4	10
108	Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S.. <i>Ethnicity and Health</i> , 2023, 28, 299-312.	1.5	10

#	ARTICLE	IF	CITATIONS
109	Race/Ethnicity and Birthplace as Risk Factors for Gastric Intestinal Metaplasia in a Multiethnic United States Population. <i>American Journal of Gastroenterology</i> , 2022, 117, 280-287.	0.2	10
110	Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2225-2232.	2.4	9
111	Associations of Duration, Intensity, and Quantity of Smoking With Risk of Gastric Intestinal Metaplasia. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e71-e76.	1.1	9
112	Time to Tailor Surveillance Intervals of Nondysplastic Barrett's Esophagus According to Segment Length and Persistence Over Multiple Endoscopies. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 832-834.	2.4	8
113	External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2387-2393.	1.1	8
114	Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 427-433.	1.1	7
115	Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1402-1409.	1.1	7
116	Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2691-2699.	1.1	6
117	Sex Differences in the Risk of Barrett's Esophagus Associated With the Metabolic Effects of Obesity. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 795-800.	1.1	6
118	Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 5695.	1.6	6
119	Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 560-562.e2.	2.4	5
120	Risk Prediction Models for Barrett's Esophagus Discriminate Well and Are Generalizable in an External Validation Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2992-2999.	1.1	5
121	Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. <i>Clinical Colorectal Cancer</i> , 2020, 19, e49-e57.	1.0	5
122	Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1600-1610.	1.1	5
123	Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. <i>PLoS ONE</i> , 2016, 11, e0169250.	1.1	4
124	Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1965-1973.	1.1	4
125	Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	4
126	Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	4

#	ARTICLE	IF	CITATIONS
127	Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Gastroenterology, 2019, 156, 809-811.	0.6	3
128	Preventable causes of cancer in Texas by race/ethnicity: Alcohol consumption. Alcohol, 2020, 85, 21-26.	0.8	3
129	Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas. Open Forum Infectious Diseases, 2020, 7, ofaa191.	0.4	3
130	Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. Veterans population. PLoS ONE, 2021, 16, e0260019.	1.1	3
131	External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointestinal Endoscopy, 2022, 95, 1113-1122.	0.5	3
132	Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer Journal, 2022, 12, .	2.8	3
133	Racial/Ethnic Differences in Cancers Attributable to Preventable Infectious Agents in Texas, 2015. Public Health Reports, 2020, 135, 805-812.	1.3	2
134	The Esophageal Adenocarcinoma Epidemic Has Reached Hungary: A Multicenter, Cross-Sectional Study. Frontiers in Oncology, 2020, 10, 541794.	1.3	2
135	Increasing Incidence of Gallbladder Cancer among Non-Hispanic Blacks in the United States: A Birth Cohort Phenomenon. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1410-1417.	1.1	2
136	Inverse Association Between Gluteofemoral Obesity and Risk of Non-Cardia Gastric Intestinal Metaplasia. Clinical Gastroenterology and Hepatology, 2023, 21, 64-71.	2.4	2
137	Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults. Digestive Diseases and Sciences, 2016, 61, 1139-1147.	1.1	1
138	Authors' reply to: Statin use and risk of liver cancer. International Journal of Cancer, 2019, 145, 2009.	2.3	1
139	Screening and Early Detection. , 2020, , 375-398.e7.		1
140	Surveillance after Treatment of Barrett's Esophagus Benefits Those with High-Grade Dysplasia or Intramucosal Cancer Most. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.2	1
141	Sociodemographic and Facility-Related Disparities in the Delivery of Guideline-Concordant Therapy Among Patients With Esophageal Adenocarcinoma. JCO Oncology Practice, 2022, 18, e1181-e1197.	1.4	1
142	Admixture mapping in African Americans identifies new risk loci for HCV-related cirrhosis. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	1
143	Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Digestive Diseases and Sciences, 2023, 68, 761-769.	1.1	1
144	Weight Change and Weight Cycling Are Not Associated With Risk of Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2016, 14, 1839-1840.	2.4	0

#	ARTICLE	IF	CITATIONS
145	Obesity in Relation to Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Current Nutrition Reports</i> , 2016, 5, 41-47.	2.1	0
146	NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?. <i>Current Hepatology Reports</i> , 2017, 16, 26-32.	0.4	0
147	Can We Accurately Predict Survival in Patients With Perihilar Cholangiocarcinoma?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1860-1862.	2.4	0
148	Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 137-139.	2.4	0
149	Editorial: less acid, less cancer? Is this the question? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 878-879.	1.9	0
150	<i>Helicobacter pylori</i> Infection and Gastroesophageal Reflux Disease's Barrett's Esophagus- Esophageal Adenocarcinoma Sequence: Reply From Authors. <i>American Journal of Gastroenterology</i> , 2018, 113, 1724-1725.	0.2	0
151	Prospective implementation of algorithmic patient selection for gastrostomy tube placement consultations: a pre- and post-intervention analysis. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 231-237.	1.0	0
152	Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1912-1914.	2.4	0
153	Response to Zhu and Xu. <i>American Journal of Gastroenterology</i> , 2020, 115, 1725-1725.	0.2	0
154	Preventable causes of cancer in Texas by race/ethnicity: insufficient physical activity. <i>BMJ Nutrition, Prevention and Health</i> , 2020, 3, 172-179.	1.9	0
155	Modest Impact of Liver Transplantation on Hepatocellular Carcinoma Mortality in the United States, Findings from The Transplant Cancer Match (TCM) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 435-437.	1.1	0
156	Preventable causes of cancer in Texas by race/ethnicity: tobacco smoking. <i>Epidemiology and Health</i> , 2021, 43, e2021046.	0.8	0
157	Preventable causes of cancer in Texas by Race/Ethnicity: Inadequate diet. <i>Preventive Medicine Reports</i> , 2021, 24, 101637.	0.8	0
158	Response to Swami et al.. <i>American Journal of Gastroenterology</i> , 2022, 117, 1012-1012.	0.2	0